Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases.
| Title: | Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases. |
|---|---|
| Authors: | Wanner A; Division of Pulmonary and Critical Care Medicine, University of Miami and Alpha-1 Foundation, Miami, Florida.; Groft SC; Division of Pulmonary and Critical Care Medicine, University of Miami and Alpha-1 Foundation, Miami, Florida.; Teagarden JR; Division of Pulmonary and Critical Care Medicine, University of Miami and Alpha-1 Foundation, Miami, Florida.; Krischer J; Division of Pulmonary and Critical Care Medicine, University of Miami and Alpha-1 Foundation, Miami, Florida.; Davis BR; Division of Pulmonary and Critical Care Medicine, University of Miami and Alpha-1 Foundation, Miami, Florida.; Coffey CS; Division of Pulmonary and Critical Care Medicine, University of Miami and Alpha-1 Foundation, Miami, Florida.; Hickam DH; Division of Pulmonary and Critical Care Medicine, University of Miami and Alpha-1 Foundation, Miami, Florida.; Teckman J; Division of Pulmonary and Critical Care Medicine, University of Miami and Alpha-1 Foundation, Miami, Florida.; Nelson DR; Division of Pulmonary and Critical Care Medicine, University of Miami and Alpha-1 Foundation, Miami, Florida.; McCaleb ML; Division of Pulmonary and Critical Care Medicine, University of Miami and Alpha-1 Foundation, Miami, Florida.; Loomba R; Division of Pulmonary and Critical Care Medicine, University of Miami and Alpha-1 Foundation, Miami, Florida.; Strange C; Division of Pulmonary and Critical Care Medicine, University of Miami and Alpha-1 Foundation, Miami, Florida.; Sandhaus RA; Division of Pulmonary and Critical Care Medicine, University of Miami and Alpha-1 Foundation, Miami, Florida.; Brantly M; Division of Pulmonary and Critical Care Medicine, University of Miami and Alpha-1 Foundation, Miami, Florida.; Edelman JM; Division of Pulmonary and Critical Care Medicine, University of Miami and Alpha-1 Foundation, Miami, Florida.; Farrugia A; Division of Pulmonary and Critical Care Medicine, University of Miami and Alpha-1 Foundation, Miami, Florida. |
| Source: | Chronic obstructive pulmonary diseases (Miami, Fla.) [Chronic Obstr Pulm Dis] 2015 Apr 28; Vol. 2 (2), pp. 177-190. Date of Electronic Publication: 2015 Apr 28. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: COPD Foundation Country of Publication: United States NLM ID: 101635411 Publication Model: Electronic Cited Medium: Print ISSN: 2372-952X (Print) Linking ISSN: 2372952X NLM ISO Abbreviation: Chronic Obstr Pulm Dis Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Publication: : Denver, CO : COPD Foundation; Original Publication: Miami, FL : COPD Foundation, [2014]- |
| Abstract: | Clinical research in rare diseases, including alpha-1 antitrypsin deficiency (AATD), faces challenges not shared by common disease research. These challenges may include the limited number of patient volunteers available for research, lack of natural history studies on which to base many clinical trial interventions, an urgency for the development of drug therapies given the often poor prognosis of rare diseases and uncertainties about appropriate biomarkers and clinical outcomes critical to clinical trial design. To address these challenges and initiate formal discussions among key stakeholders-patients, researchers, industry, federal regulators-the Alpha-1 Foundation hosted the Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases conference February 3-4, 2014 in Bethesda, Maryland. Discussions at the conference led to the conclusions that 1) adaptive designs should be considered for rare disease clinical trials yet more dialogue and study is needed to make these designs feasible for smaller trials and to address current limitations; 2) natural history studies, including the identification of appropriate biomarkers are critically needed and precompetitive collaborations may offer a means of creating these costly studies; and 3) patient registries and databases within the rare disease community need to be more publicly available and integrated, particularly for AATD. This report summarizes the discussions leading to these conclusions. |
| Competing Interests: | Dr. Brantley has received research funding from the Alpha-1 Foundatioin, Baxter Biologics, Grifols, Kamada Ltd, AGTC and CSL Behring. Dr. Edelman is an employee of CSL Behring Pharmaceuticals. Dr. McCaleb is an employee of Isis Pharmaceuticals. No other authors had any conflict of interests to declare. |
| References: | Am J Respir Crit Care Med. 1996 Nov;154(5):1290-5. (PMID: 8912738); Sci Transl Med. 2010 Oct 6;2(52):52cm26. (PMID: 20926831); J Biol Chem. 2012 Nov 2;287(45):38265-78. (PMID: 22995909); Gastroenterology. 2005 Feb;128(2):343-50. (PMID: 15685546); Ann Clin Biochem. 1992 Jan;29 ( Pt 1):72-8. (PMID: 1536530); Milbank Q. 2010 Jun;88(2):256-76. (PMID: 20579285); Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12941-3. (PMID: 14563926); JAMA. 2003 Mar 12;289(10 ):1278-87. (PMID: 12633190); Eur Respir J. 2012 Sep;40(3):561-9. (PMID: 22700846); Gastroenterology. 2011 Jun;140(7):1970-9, 1979.e1-3. (PMID: 21376047); JAMA. 2002 Dec 18;288(23):2998-3007. (PMID: 12479764); JAMA. 2002 Dec 18;288(23):2981-97. (PMID: 12479763); Sci Transl Med. 2014 Jan 1;6(217):217ra1. (PMID: 24382893); N Engl J Med. 1976 Jun 10;294(24):1316-21. (PMID: 1083485); J Clin Invest. 2014 Jan;124(1):251-61. (PMID: 24355919); Am J Respir Crit Care Med. 2003 Oct 1;168(7):818-900. (PMID: 14522813); COPD. 2006 Mar;3(1):17-23. (PMID: 17175661); Am J Respir Cell Mol Biol. 2008 Jan;38(1):114-20. (PMID: 17690329); COPD. 2009 Jun;6(3):177-84. (PMID: 19811373); Hepatology. 2012 Sep;56(3):922-32. (PMID: 22431131); Hepatology. 2014 Dec;60(6):1920-8. (PMID: 25103310); Genet Med. 2004 Jul-Aug;6(4):204-10. (PMID: 15266208); COPD. 2013 Aug;10(4):473-81. (PMID: 23560990); Magn Reson Imaging. 2015 Jan;33(1):26-30. (PMID: 25308096); Intern Med. 2002 Mar;41(3):181-5. (PMID: 11929177); J Biol Chem. 2001 Sep 21;276(38):35494-9. (PMID: 11461907); Clin Pharmacol Ther. 2010 May;87(5):521-3. (PMID: 20407454); J Med Philos. 2002 Dec;27(6):651-73. (PMID: 12607162); Chest. 2007 May;131(5):1363-71. (PMID: 17494786); J Magn Reson Imaging. 2013 Nov;38(5):1215-23. (PMID: 23281116); Am Rev Respir Dis. 1992 May;145(5):1077-81. (PMID: 1586050); Stat Med. 2006 Dec 30;25(24):4279-92. (PMID: 16947139); Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):762-6. (PMID: 1554198); N Engl J Med. 2005 May 12;352(19):2030-1. (PMID: 15888711); Gastroenterology. 2008 Apr;134(4):960-74. (PMID: 18395077); Lancet. 2001 Apr 7;357(9262):1069-75. (PMID: 11297957); Am J Epidemiol. 2009 Oct 15;170(8):1005-13. (PMID: 19726494); Respir Res. 2009 Feb 25;10:12. (PMID: 19243601); Trials. 2012 Aug 23;13:145. (PMID: 22917111); Trends Mol Med. 2012 Nov;18(11):634-43. (PMID: 23026741); Eur Respir J. 1997 Oct;10(10):2260-3. (PMID: 9387950); Hepatology. 2015 Apr;61(4):1239-50. (PMID: 25482832) |
| Contributed Indexing: | Keywords: (COPD); alpha-1 antitrypsin deficiency,clinical trial design,clinical trials,rare disease research,adaptive trial design,pre-competitive trial design,patient registries; community acquired pneumonia (CAP); mortality |
| Entry Date(s): | Date Created: 20170830 Latest Revision: 20200929 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC5556970 |
| DOI: | 10.15326/jcopdf.2.2.2015.0132 |
| PMID: | 28848840 |
| Database: | MEDLINE |
Journal Article